Parkman Healthcare Partners LLC Has $14.88 Million Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Parkman Healthcare Partners LLC lessened its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 13.3% during the third quarter, HoldingsChannel.com reports. The firm owned 130,249 shares of the company’s stock after selling 19,942 shares during the quarter. Vaxcyte makes up about 1.9% of Parkman Healthcare Partners LLC’s holdings, making the stock its 18th biggest holding. Parkman Healthcare Partners LLC’s holdings in Vaxcyte were worth $14,884,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Blue Trust Inc. boosted its position in shares of Vaxcyte by 33.5% during the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company’s stock worth $42,000 after acquiring an additional 93 shares in the last quarter. Nisa Investment Advisors LLC boosted its position in shares of Vaxcyte by 5.2% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,209 shares of the company’s stock worth $252,000 after acquiring an additional 110 shares in the last quarter. CIBC Asset Management Inc boosted its position in shares of Vaxcyte by 3.6% during the 3rd quarter. CIBC Asset Management Inc now owns 3,136 shares of the company’s stock worth $358,000 after acquiring an additional 110 shares in the last quarter. Amalgamated Bank boosted its position in shares of Vaxcyte by 4.2% during the 2nd quarter. Amalgamated Bank now owns 3,759 shares of the company’s stock worth $284,000 after acquiring an additional 150 shares in the last quarter. Finally, Riverview Trust Co acquired a new stake in shares of Vaxcyte during the 3rd quarter worth approximately $27,000. Institutional investors and hedge funds own 96.78% of the company’s stock.

Vaxcyte Stock Down 1.3 %

Shares of NASDAQ PCVX opened at $90.37 on Wednesday. Vaxcyte, Inc. has a twelve month low of $52.74 and a twelve month high of $121.06. The firm has a fifty day simple moving average of $104.69 and a 200 day simple moving average of $90.71. The company has a market capitalization of $11.26 billion, a PE ratio of -19.65 and a beta of 0.94.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter in the prior year, the company posted ($0.91) EPS. As a group, equities analysts expect that Vaxcyte, Inc. will post -4.14 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PCVX has been the subject of several research reports. BTIG Research increased their price objective on shares of Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Jefferies Financial Group increased their price objective on shares of Vaxcyte from $108.00 to $129.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Bank of America raised their price target on shares of Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, September 4th. Finally, Leerink Partners raised their price target on shares of Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a research note on Tuesday, September 3rd. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $147.50.

Insider Buying and Selling

In other Vaxcyte news, SVP Mikhail Eydelman sold 5,000 shares of the firm’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $109.27, for a total value of $546,350.00. Following the completion of the sale, the senior vice president now directly owns 28,623 shares in the company, valued at approximately $3,127,635.21. This trade represents a 14.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Grant Pickering sold 15,000 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $92.45, for a total transaction of $1,386,750.00. Following the completion of the sale, the chief executive officer now owns 450,301 shares of the company’s stock, valued at $41,630,327.45. The trade was a 3.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 110,464 shares of company stock valued at $11,924,596 over the last quarter. Insiders own 3.10% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.